SGLT抑制剂在1型糖尿病中的辅助治疗
1型糖尿病的非胰岛素辅助治疗旨在改善血糖控制并降低低血糖风险,但证据有限。近期DEPICT-1和inTandem3两项随机对照试验显示,达格列净和索格列净辅助治疗可使HbA1c降低5-6 mmol/mol(0.4-0.5%),伴体重减轻和每日胰岛素总剂量减少,不显著增加低血糖风险,但增加糖尿病酮症酸中毒和真菌感染风险。
要点
- SGLT抑制剂辅助治疗1型糖尿病可降低HbA1c 5-6 mmol/mol(0.4-0.5%),伴体重减轻和胰岛素剂量减少。
- HbA1c降低不伴随低血糖风险显著增加,但糖尿病酮症酸中毒和真菌感染风险增加。
- 需≥52周长期临床试验和观察性队列研究确定额外获益或不良反应及最受益人群。
核心结论
- SGLT抑制剂在1型糖尿病管理中可能有一席之地,但需长期研究确定额外获益或不良反应及最受益人群。
研究设计与样本
- 基于近期短期II期试验和24周III期试验,包括两项国际多中心随机对照临床试验DEPICT-1和inTandem3。
主要发现
- DEPICT-1和inTandem3分别报告达格列净和索格列净辅助治疗使HbA1c降低5-6 mmol/mol(0.4-0.5%),伴体重减轻和每日胰岛素总剂量减少。
- HbA1c降低不伴随低血糖风险显著增加,但糖尿病酮症酸中毒和真菌感染风险增加。
临床怎么用
- SGLT抑制剂辅助治疗1型糖尿病需特定的患者和医护人员教育方案以确保患者安全并最小化风险。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Non-insulin adjunct therapies in type 1 diabetes have been proposed as a means of improving glycaemic control and reducing risk of hypoglycaemia. Evidence to support this approach is, however, scant and few pharmacological agents have proved effective enough to become part of routine clinical care. Recent short-term Phase II trials and 24 week Phase III trials provide initial support for the use of sodium-glucose cotransporter (SGLT) inhibitors in type 1 diabetes. Two international, multicentre, randomised, controlled clinical trials, Dapagliflozin Evaluation in Patients with Inadequately Controlled Type 1 Diabetes (DEPICT-1) and inTandem3, have reported that SGLT inhibition with dapagliflozin and sotagliflozin, respectively, confer additional benefits in terms of a 5-6 mmol/mol (0.4-0.5%) reduction in HbA1c accompanied by weight loss and reductions in total daily insulin doses. The reduction in HbA1c does not come with a significantly increased risk of hypoglycaemia but does carry an increased risk of diabetic ketoacidosis and mycotic infections. These results suggest that SGLT inhibition will have a place in the management of type 1 diabetes. Longer-term clinical trials (≥52 weeks) and observational cohort studies are needed to determine any additional benefits or adverse effects of this adjunct therapy and to determine which group of patients may benefit most from this approach. In addition, use of SGLT inhibitors in routine type 1 diabetes care will require specific patient and healthcare professional educational packages to ensure patient safety and to minimise risk.
引用
- McCrimmon RJ, Henry RR. SGLT inhibitor adjunct therapy in type 1 diabetes. Diabetologia. 2018. PMID: 30132030. doi:10.1007/s00125-018-4671-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。